Corrigendum to "ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway" [Cancer Lett. 454 (2019) 179-190]
Cancer Lett. 2019 Oct 1:461:153-154.
doi: 10.1016/j.canlet.2019.05.002.
Epub 2019 May 16.
1 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China.
2 Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, Chengdu, 610041, China.
3 Department of Gastroenterology, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China.
4 National Chengdu Center for Safety Evaluation of Drugs, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
5 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China. Electronic address: yangsy@scu.edu.cn.
6 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China. Electronic address: zhaoyinglan@scu.edu.cn.